Nivolumab and ipilimumab treatment in prostate cancer with an immunogenic signature (NEPTUNES).

Yien Ning Sophia Wong,Peter Sankey,Debra H. Josephs,Robert Jones,Simon J. Crabb,Sandy Beare,Marian Duggan,Laura White,Nikolaos Charlaftis,Graham M. Wheeler,Josep Linares,Sergio A. Quezada,Leah Ensell,Cliona Flanagan,Bihani Yoshana Kularatne,Moon Chung,Colin C. Pritchard,Alex Freeman,Teresa Marafioti,Mark Linch

Nivolumab and ipilimumab treatment in prostate cancer with an immunogenic signature (NEPTUNES).

2019

TPS5090Background: Responses to checkpoint inhibitor (CPI) monotherapy in patients with metastatic castration resistant prostate cancer (mCRPC) have been limited. This is in part attributed to low ...

Keywords:

Prostate cancer
Pathology
Ipilimumab
Nivolumab
Oncology
Internal medicine
Medicine
in patient
castration resistant
immune checkpoint inhibitors

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations